

Hansa Medical

- PRESS RELEASE -
May 12, 2016

Hansa Medical appoints Henk Doude van Troostwijk as Vice President, Commercial Operations

Hansa Medical AB (publ) announced today the appointment of Henk Doude van Troostwijk as Vice President, Commercial Operations to strengthen its management team.

Henk's key focus will be on the company's commercial assessments of its lead project IdeS, including market access, pricing and re-imburement aspects. IdeS is now in Phase II clinical development focused on kidney transplantation in sensitized patients.

"We are very excited that Henk will engage in Hansa Medical, as we now start to prepare our commercialization strategy for IdeS", said Göran Arvidson, President and CEO of Hansa Medical.

Henk has significant management experience in sales and marketing from the areas of transplantation and orphan drugs. Lately, Henk has served as Business Unit Director Oncology and Transplantation at Genzyme and most recently as General Manager of European Commercial Operations and Emerging Markets at Raptor Pharmaceuticals, an orphan disease focused global biopharma company based in the US. Henk holds an MBA from Henley Management College at the University of Reading, UK

Besides Henk, the management team of Hansa Medical consists of:

Göran Arvidson	President and CEO
Christian Kjellman	Senior Vice President, Research and Development
Emanuel Björne	Vice President, Business Development and Investor Relations
Steven Glazer	Vice President, Chief Medical Officer
Eva-Maria Joed	Vice President, Chief Financial Officer
Lena Winstedt	Vice President, Project Management

About Hansa Medical AB

Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory enzymes. The lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Additional projects focus on development of new antibody modulating enzymes, as well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency departments that is already introduced on the market. The company is based in Lund, Sweden. Hansa Medical's share (ticker: HMED) is listed on Nasdaq Stockholm.

For further information, please contact:

Göran Arvidson, CEO, Hansa Medical AB (publ)
Mobile: +46 70-633 30 42
E-mail: goran.arvidson@hansamedical.com

The information in this press release is disclosed pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was released for public disclosure on May 12, 2016 at 08.30 CET.